PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.

Saved in:
Bibliographic Details
Title: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.
Authors: Patel AJ; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Warda S; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Maag JLV; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York., Misra R; Department of Genetics, Albert Einstein College of Medicine, Bronx, New York., Miranda-Román MA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York., Pachai MR; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Lee CJ; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Li D; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Wang N; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Bayshtok G; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Fishinevich E; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Meng Y; Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, New York., Wong EWP; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Yan J; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Giff E; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Pappalardi MB; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, Pennsylvania., McCabe MT; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, Pennsylvania., Fletcher JA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Rudin CM; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Chandarlapaty S; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Medical College, New York, New York., Scandura JM; Laboratory of Molecular Hematopoiesis, Hematology and Oncology, Weill Cornell Medicine, New York, New York.; Richard T. Silver MD Myeloproliferative Neoplasm Center, Weill Cornell Medicine, New York, New York.; Regenerative Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York., Koche RP; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York., Glass JL; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York., Antonescu CR; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Zheng D; The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York.; Department of Genetics, Albert Einstein College of Medicine, Bronx, New York.; Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York., Chen Y; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, New York.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York., Chi P; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, New York.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York.
Source: Cancer discovery [Cancer Discov] 2022 Sep 02; Vol. 12 (9), pp. 2120-2139.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2159-8290
DOI:10.1158/2159-8290.CD-21-1671